Immunohematology Testing segmentation by application reveals four primary demand drivers that collectively define the market’s revenue composition. Blood transfusion compatibility, encompassing ABO/Rh typing, antibody identification and cross‑matching, commands the largest share at roughly 40 % of total spend, reflecting its mandatory role in hospital transfusion services and the high volume of routine tests performed. Infectious disease screening, which integrates serologic assays for hepatitis B, C, HIV and emerging pathogens, accounts for about 30 % of the market, driven by regulatory mandates and the growing emphasis on blood safety. Autoimmune disorder diagnosis, including assays for hemolytic disease of the newborn and autoimmune hemolytic anemia, contributes an estimated 20 %, as specialty clinics adopt more sophisticated panels to guide therapy. The remaining 10 % is allocated to research and development activities, where academic and commercial laboratories employ advanced immunohematology platforms for biomarker discovery and method validation. Consequently, shifts in transfusion protocols or infection‑control guidelines directly translate into measurable changes in market growth rates. These proportions are illustrated in the accompanying pie‑chart.